SCHEMBL3071356

SCHEMBL3071356

C1CCCPCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3069990 1.00
SCHEMBL3073102 1.00
SCHEMBL3063066 1.00
SCHEMBL3065206 1.00
SCHEMBL3081454 1.00
SCHEMBL3064662 1.00
SCHEMBL3074060 1.00
SCHEMBL3082494 1.00
SCHEMBL3066661 1.00
SCHEMBL3073335 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026044399-A1 ANTIBODIES TARGETING CENTRAL NERVOUS SYSTEM LOCALIZED ANTIGENS SINGH SIDHU SACHDEV (CA) 2026-03-05 WO disclosed
US-12491256-B2 Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof BLUEFIN BIOMEDICINE, INC. (US) 2025-12-09 US disclosed
US-20250360129-A1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-11-27 US disclosed
EP-4653015-A2 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS Yale University (US) 2025-11-26 EP disclosed
EP-3250192-B1 COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS UNIV YALE (US) 2025-10-08 EP disclosed
EP-4626441-A1 PHARMACEUTICAL COMBINATIONS AND USES THEREOF The University of Melbourne (AU) 2025-10-08 EP disclosed
US-20250295731-A1 SOY-DERIVED BIOACTIVE PEPTIDES FOR USE IN COMPOSITIONS AND METHODS FOR WOUND HEALING, TISSUE ENGINEERING, AND REGENERATIVE MEDICINE TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-09-25 US disclosed
EP-4608411-A1 METHODS OF TREATING INSULIN RESISTANCE AND ASSOCIATED DISORDERS The University of Melbourne (AU) 2025-09-03 EP disclosed
WO-2024113004-A9 PHARMACEUTICAL COMBINATIONS AND USES THEREOF THE UNIVERSITY OF MELBOURNE (AU) 2025-06-26 WO disclosed
US-12251420-B2 Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine Temple University—Of the Commonwealth System of Higher Education (US) 2025-03-18 US disclosed
US-20030004285-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2003-01-02 US disclosed
US-6465383-B2 COORDINATION CATALYST EASTMAN CHEMICAL COMPANY 2002-10-15 US disclosed
US-20010051587-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2001-12-13 US disclosed
US-20010031841-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2001-10-18 US disclosed
US-20010029286-A1 Procatalysts, catalyst systems, and use in OLEFIN polymerization EASTMAN CHEMICAL COMPANY, A CORP. OF DELAWARE 2001-10-11 US disclosed
US-20010025005-A1 Procatalysts, catalyst systems, and use in olefin polymerization EASTMAN CHEMICAL COMPANY, A CORPORATION OF DELAWARE 2001-09-27 US disclosed
WO-2001051526-A1 PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION EASTMAN CHEMICAL COMPANY (US) 2001-07-19 WO disclosed
WO-2001051527-A1 PROCATALYSTS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION EASTMAN CHEMICAL COMPANY (US) 2001-07-19 WO disclosed
WO-2001051529-A1 PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION EASTMAN CHEMICAL COMPANY (US) 2001-07-19 WO disclosed
WO-2001051528-A1 PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION EASTMAN CHEMICAL COMPANY (US) 2001-07-19 WO disclosed